Tests small drug doses inside bladder tumors using tiny implanted devices
Tiny devices release microdoses of cancer drugs into bladder tumors in adults.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Drug Screening Using IMD in Bladder Cancer
- Status
- Enrolling by invitation
- Phase
- Early phase 1
- People taking part
- 18 people, planned
- Started
- 14 Jun 2024
- Expected to end
- 1 Aug 2028
- Type of study
- Interventional
- Treatments tested
- Implantable Micro-Device
- Methotrexate
- Carboplatin
- Avelumab
- Paclitaxel
- Vinblastine
- Gemcitabine/Cisplatin I
- Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab
- Gemcitabine/Cisplatin II
- Cisplatin
- Nivolumab
- Pembrolizumab
- Gemcitabine/Carboplatin
- Methotrexate/Vinblastine/Doxorubicin/Cisplatin
- Gemcitabine/Cisplatin/Nivolumab
- Erdafitinib
- Paclitaxel/Docetaxel/Ifosfamide
- Gemcitabine
- Gemcitabine/Carboplatin/Nivolumab
- Enfortumab
- Sacituzumab
- Record updated
- 18 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bladder cancer that has not spread, who are already planned for bladder removal surgery. Tiny devices are placed in the tumor to test drug response.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Bladder cancer (urothelial carcinoma or a variant type) that is only in the bladder area, imaging consistent with stage T2-T3 N0. The tumor planned for removal must be at least 1cm (0.4 in).
- Earlier treatment
- Must be planned for cystectomy (bladder removal surgery) as part of regular care. A medical oncologist decides the treatment plan.
- Biomarker or test result
- Blood tests within 30 days before the procedure: absolute neutrophil count ≥1,000/mcL, platelets ≥50,000/mcL, PT (INR) 1.5, PTT <1.5x control. Must agree to genetic sequencing.
Main reasons for not taking part
- Uncontrolled illness, such as active infection, symptomatic heart failure, unstable angina, unstable heart rhythm, or psychiatric illness or social situations that limit the safety of biopsy or surgery
- Bleeding or clotting disorder that cannot be corrected and raises risk with surgery or biopsy
- Not medically stable for the needle procedure and surgery
- Tumor that cannot be reached by needle or removed at surgery
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients must have the ability to understand and the willingness to sign a written informed consent document
- Participants must have confirmed clinically localized bladder cancer with histology of urothelial cell carcinoma or variant histology and radiographic imaging consistent with stage T2-T3 N0 disease. Patients must be planned for cystectomy as part of their clinical care. The lesion planned for excision must be at least 1cm in size
- Participants must be 18 years of age or older. Patients must have the ability to understand and the willingness to sign a written informed consent document
- Participants must have confirmed clinically localized bladder cancer with histology of urothelial cell carcinoma or variant histology and radiographic imaging consistent with stage T2-T3 N0 disease. Patients must be planned for cystectomy as part of their clinical care. The lesion planned for excision must be at least 1cm in size
- Participants must be 18 years of age or older. Patients must have the ability to understand and the willingness to sign a written informed consent document
- Participants must have confirmed clinically localized bladder cancer with histology of urothelial cell carcinoma or variant histology and radiographic imaging consistent with stage T2-T3 N0 disease. Patients must be planned for cystectomy as part of their clinical care. The lesion planned for excision must be at least 1cm in size
- Participants must be 18 years of age or older
- Participants must be evaluated by a medical oncologist who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease
- Patients must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures
- Participants will undergo laboratory testing within 30 days prior to the procedure (or within 72 hours if there has been a change in the clinical status since the initial blood draw). Patients must have absolute neutrophil count ≥1,000/mcL, platelets ≥50,000/mcL, PT (INR) 1.5 and PTT<1.5x control
- Participants must have undergone CT or MRI that assesses the extent of disease and allows the research team to assess for study eligibility. This will have been done as part of the standard-of-care
- The participant's case must be reviewed by the treating physician to assess the following factors:; Patient is clinically stable to undergo microdevice implantation and surgical procedures; Patient has sufficient volume of disease to allow implantation of the microdevice; Patient has a lesion for which the microdevice is a) amenable to percutaneous placement, and b) amenable to removal at the time of surgery
- Patients must be willing to undergo research-related genetic sequencing (somatic and germline) and data management, including the deposition of de-identified genetic sequencing data in NIH central data repositories
- Patients must be agree to remain abstinent or use contraceptive measures for the duration of the study period
Who cannot take part
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery
- Uncorrectable bleeding or coagulation disorder known to cause increased risk with surgical or biopsy procedures (detailed below in section 5.1.2.1)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 120 years old?
Where in United States
- Brigham and Women's HospitalBoston, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor. These devices will release microdoses (many thousands of times less than a treatment dose) of different cancer drugs into the tumor. After approximately 72 hours, the devices and small regions of surrounding tissue will be removed and studied. There will be a follow-up visit within 42 days of device removal to assess for potential safety issues or side effects.
The group in the trial
- DRUG SCREENING USING IMD IN BLADDER CANCERTreatment being tested
Study participants placed in arm 1 will be implanted with the microdevice.
Treatment: Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, and Enfortumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Primary Bladder Tumors
- Plain-language title
- Tests small drug doses inside bladder tumors using tiny implanted devicesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06204614, who can take part
- Record updated
- 18 May 2026